Comparison between Agilus Diagnostics IPO and Corona Remedies IPO.
Agilus Diagnostics IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Corona Remedies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Agilus Diagnostics IPO is up to ₹0.00 Cr whereas the issue size of the Corona Remedies IPO is up to ₹655.37 Cr. The final issue price of Agilus Diagnostics IPO is and of Corona Remedies IPO is ₹1,062.00 per share.
| Agilus Diagnostics IPO | Corona Remedies IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹1,008.00 per share | |
| Issue Price (Upper) | ₹1,062.00 per share | |
| Issue Price (Final) | ₹1,062.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | |
| Market Lot Size | 14 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 1,42,33,964 shares | 61,74,051 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹655.37 Cr |
| Issue Size Total | 1,42,33,964 shares | 61,74,051 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹655.37 Cr |
Agilus Diagnostics IPO opens on , while Corona Remedies IPO opens on Dec 08, 2025. The closing date of Agilus Diagnostics IPO and Corona Remedies IPO is , and Dec 10, 2025, respectively.
| Agilus Diagnostics IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Bid Date | Dec 05, 2025 | |
| Issue Open | Dec 08, 2025 | |
| Issue Close | Dec 10, 2025 | |
| Basis Of Allotment (Tentative) | Dec 11, 2025 | |
| Initiation of Refunds (Tentative) | Dec 12, 2025 | |
| Credit of Share (Tentative) | Dec 12, 2025 | |
| Listing date (Tentative) | Dec 15, 2025 | |
| Anchor Lockin End date 1 | Jan 09, 2026 | |
| Anchor Lockin End date 2 | Mar 10, 2026 |
Agilus Diagnostics IPO P/E ratio is , as compared to Corona Remedies IPO P/E ratio of 43.47.
| Agilus Diagnostics IPO | Corona Remedies IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 57.68 | 72.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 43.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6495.20 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 6.12% | 27.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 20.17% | 41.32% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹24.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 6.61% | 24.65% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Agilus Diagnostics IPO Retail Individual Investors (RII) are offered while in Corona Remedies IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Agilus Diagnostics IPO and 12,23,203 shares in Corona Remedies IPO.
| Agilus Diagnostics IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,34,804 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 12,23,203 shares | |
| NII | 9,17,403 shares | |
| RII | 21,40,606 shares | |
| Employee | 58,035 shares | |
| Others | ||
| Total | 61,74,051 shares |
Agilus Diagnostics IPO subscribed in total, whereas Corona Remedies IPO subscribed 144.54x.
| Agilus Diagnostics IPO | Corona Remedies IPO | |
|---|---|---|
| QIB (times) | 293.80x | |
| NII (times) | 220.18x | |
| Big NII (times) | 246.67x | |
| Small NII (times) | 167.20x | |
| RII (times) | 30.39x | |
| Employee (times) | 15.56x | |
| Other (times) | ||
| Total (times) | 144.54x |
